References
- Sumi M, Ichikawa N, Shimizu I, et al. Successful treatment with interferon-alpha-2b and imatinib in an adult Japanese male with Philadelphia chromosome-positive acute lymphoblastic leukemia and minimal residual disease following allogeneic transplantation. Bone Marrow Transplant. 2008; 41:827–829.
- Ravandi F, O'Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121:4158–4164.
- Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–956.
- Naik S, Martinez C, Leung K, et al. Outcomes after second hematopoietic stem cell transplantations in pediatric patients with relapsed hematological malignancies. Biol Blood Marrow Transplant. 2015;21:1266–1272.
- Kato M, Horikoshi Y, Okamoto Y, et al. Second allogeneic hematopoietic SCT for relapsed ALL in children. Bone Marrow Transplant. 2012;47:1307–1311.
- Mo XD, Zhang XH, Xu LP, et al. Interferon-α: a potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:1939–1947.
- de Lavallade H, Khorashad JS, Davis HP, et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood. 2007;110:2779–2780.
- Wang Y, Xue MX, Wu XH, et al. Successful treatment of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia with T315I mutation after haplo-identical hematopoietic stem cell transplantation with donor lymphocyte transfusion and interferon-alpha-2b. Leuk Res. 2009;33:e111–e113.
- Itonaga H, Tsushima H, Hata T, et al. Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. Int J Hematol. 2012;95:209–213.
- Ilander M, Koskenvesa P, Hernesniemi S, et al. Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy. Leuk Lymphoma. 2014;55:934–937.
- Polivkova V, Rohon P, Klamova H, et al. Interferon-α revisited: individualized treatment management eased the selective pressure of tyrosine kinase inhibitors on BCR-ABL1 mutations resulting in a molecular response in high-risk CML patients. PLoS One. 2016;11:e0155959.
- Soverini S, De Benedittis C, Papayannidis C, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120:1002–1009.
- Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–1796.
- Sanford DS, Kantarjian H, O'Brien S, et al. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015;15:365–373.
- Renzi D, Marchesi F, De Angelis G, et al. Ponatinib induces a persistent molecular response and graft-versus-host disease/graft-versus-leukemia effect in a patient with philadelphia-positive acute lymphoblastic leukemia with a T315I mutation following early relapse after allogeneic transplant. Chemotherapy. 2016;62:58–61.